Video

Dr Peter Bach Explains Diminishing Returns in Cancer Drugs

While the cost of introductory cancer drugs is increasing rapidly, there has not been a commensurate increase in benefit, according to Peter Bach, MD, with Memorial Sloan Kettering Cancer Center.

Over the years the cost of gaining a year with a new cancer drug has gone up to $8500. However, while the cost of introductory cancer drugs is increasing rapidly, there has not been a commensurate increase in benefit, according to Peter Bach, MD, with Memorial Sloan Kettering Cancer Center.

Healthcare is the only sector where a product is becoming more expensive while being incrementally less efficient, he said.

“What we see is what economists would call ‘diminishing returns,’” Dr Bach said. “Or you could look at it the other way: higher charges for health benefits.”

Related Videos
Wanmei Ou, PhD, vice president of product, data analytics, and AI at Ontada
Screenshot of Susan Wescott, RPh, MBA
Glenn Balasky, executive director of the Rocky Mountain Cancer Center.
Screenshot of an interview with Adam Colborn, JD
Screenshot of an interview with James Chambers, PhD
Screenshot of an interview with Megan Ehret, PharmD
Interview screenshot with Megan Ehret, PharmD
Screenshot of an interview with Susan Wescott, RPh, MBA
Screenshot of an interview with Nadine Barrett, PhD
Female doctor in coat with stethoscope on blue background - Pixel-Shot - stock.adobe.com
Related Content
AJMC Managed Markets Network Logo
CH LogoCenter for Biosimilars Logo